This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Retain Inari Medical (NARI) for Now
by Zacks Equity Research
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inari's (NARI) Expanding Product Portfolio Offsets Competition
by Zacks Equity Research
Inari's (NARI) VTE products are driving its top line on the back of robust adoption. The company is expanding in additional indications to fuel growth and fight competition.
Inari Medical (NARI) Sues Truvic on Patent Infringement
by Zacks Equity Research
Inari Medical (NARI) files a patent infringement lawsuit against Imperative Care and its subsidiary Truvic over intentionally copying and overlapping the designs of Inari Medical's products.
Here's Why You Should Retain Inari Medical (NARI) for Now
by Zacks Equity Research
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
Inari Medical (NARI) Q1 Earnings Miss Estimates, OpEx Rises
by Zacks Equity Research
Inari Medical's (NARI) first-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the companies continue to incur operating losses.
Inari Medical, Inc. (NARI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inari Medical (NARI) delivered earnings and revenue surprises of -136.36% and 3.53%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 5 Medical Device Stocks in Q1 Earnings?
by Indrajit Bandyopadhyay
Here is a sneak peek into how the five medical device stocks, SYK, GEHC, ECL, NARI and MMSI, might fare in their quarterly results slated to be released tomorrow.
Why You Should Retain Inari Medical (NARI) Stock for Now
by Zacks Equity Research
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
Inari Medical (NARI) Up 4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inari Medical (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inari Medical's (NARI) ClotTriever Improves Patient Outcome
by Zacks Equity Research
Inari Medical (NARI) announces two-year interim results from the CLOUT registry, which shows a significant improvement in patient's post-thrombotic syndrome and lower rethrombosis-related events.
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.
Inari Medical (NARI) Q4 Earnings Improve Y/Y, Gross Margin Down
by Zacks Equity Research
Inari Medical's (NARI) fourth-quarter earnings miss, while sales match estimates. Gross margin improves while the company incurs losses at the operating level.
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 9.43% and 1.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.
Inari (NARI) Preliminary Q4 Revenues Ride on Procedure Demand
by Zacks Equity Research
Inari's (NARI) preliminary revenues reflect healthy procedure volume growth on the back of the rising adoption of existing and newly launched products in the United States and international markets.
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is a concern.
Why Is Steris (STE) Down 3.4% Since Last Earnings Report?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inari Medical, Inc. (NARI) Up 17.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inari Medical's (NARI) PEERLESS II RCT to Boost Patient Outcome
by Zacks Equity Research
Inari Medical's (NARI) latest announcement of first patient enrollment in PEERLESS II RCT is likely to aid in changing guidelines in treating intermediate-risk PE patients globally.
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is a concern.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX), led by growing demand for WATCHMAN FLX devices and upbeat guidance.
Alcon (ALC) Unveils New Progress in Presbyopia Correcting IOLs
by Zacks Equity Research
Alcon's (ALC) Clareon Vivity IOL highlights proven results and high levels of patient satisfaction. It will offer a similar halo profile compared with a monofocal IOL.
Charles River's (CRL) Q3 Earnings Beat, Margins Decline
by Zacks Equity Research
Charles River's (CRL) RMS organic revenue growth is primarily driven by research model services, particularly the Insourcing Solutions business.
Globus Medical (GMED) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Globus Medical's (GMED) legacy business continues to drive share growth across its U.S. spine and trauma portfolios in the third quarter.